Further loss after a reduction can undo the results, so timing the procedure matters
Many people need long-term or indefinite treatment to maintain weight loss
[3] Latest Developments in Oral Weight Loss Drugs Novo NordiskAmycretin On September 11, 2024, Novo Nordisk presented the first phase 1 study results for the oral weight loss drug Amycretin (NN9487) at the European Association for the Study of Diabetes (EASD) annual meeting
GLP-1 medications and significant weight loss can increase the risk of gallstones, which may present with right upper abdominal pain, fever, and sometimes jaundice
Given the substantial overlap between the neural circuits governing appetite and those involved in addictive behaviors, it is plausible that appetite-regulating peptides such as GLP-1 contribute to reduced alcohol cravings and intake, an effect that has been especially evident in individuals with obesity